-
Clinical Trials & Development2 months agoTYK2 inhibitor miss pushes Alumis toward precision strategy for lupus
BIOCENTURY | PRODUCT DEVELOPMENTTYK2 INHIBITOR MISS PUSHES ALUMIS TOWARD PRECISION STRATEGY FOR LUPUSSubgroup signal suggests IFN enrichment could rescue envudeucitinib’s Phase II all-comers miss — a strategy...
-
Clinical Trials & Development2 months agoNovartis Remibrutinib, a High-Efficacy Oral BTK Inhibitor, Significantly Reduces Relapse Rates and Shows Favorable Safety Profile in Phase III RMS Trials
Basel, September 1, 2026 – Novartis today announced positive topline results from its Phase III REMODEL-1/-2 trials of remibrutinib in relapsing multiple sclerosis.1 Remibrutinib, a highly...
-
Clinical Trials & Development2 months agoESC 2026: The drug development readouts that stood out
Find out what came out of the ESC Congress 2026, from phase 3 successes and failures to earlier-stage programs. The post ESC 2026: The drug development readouts...
Clinical Trials & Development13 hours ago
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
Clinical Trials & Development13 hours ago
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
Helixgate Featured14 hours ago
STAT+: HHS moves to allow compounding of some unapproved peptides
Uncategorized7 months ago
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Endpoints News7 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Uncategorized6 months ago
